Exane Derivatives Blueprint Medicines Corp Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Exane Derivatives holds 8 shares of BPMC stock, worth $1,035. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8
Previous 567
98.59%
Holding current value
$1,035
Previous $36,000
100.0%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
40Shares Held
8.54MCall Options Held
0Put Options Held
14.8K-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8724KShares$93.7 Million0.05% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL419KShares$54.3 Million0.01% of portfolio
-
Eagle Asset Management Inc St Petersburg, FL155KShares$20 Million0.09% of portfolio
-
Ghost Tree Capital, LLC New York, NY140KShares$18.1 Million4.85% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...